Topotarget announces the date for the H1 2010 interim report and a related telephone conference

Topotarget A/S
Symbion
Fruebjergvej 3
DK-2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com


Copenhagen, Denmark - 13 August 2010 - Topotarget A/S (NASDAQ OMX: TOPO)
announces that the interim report for H1 2010 will be released on 19 August
2010. On the same day a teleconference will be held at 2:00 pm local time,
where CEO Francois Martelet and CFO Anders Vadsholt will present the H1 2010
interim report and answer questions. The teleconference will be conducted in
English. A presentation will be available on Topotarget's website,
www.topotarget.com, before the start of the conference call. 

To participate in the conference call please dial:
-	From Denmark: 32 71 47 67 
- 	Outside Denmark: +45 70 26 50 40 or 0800 634 5205 (UK) or 1866 629 2704 (US)
or 0200 125 785 (SE) 

A replay of the conference call will be available approximately two hours after
the conference call and until 17 November 2010 at: +353 1 436 4267 or +44 207
769 6425, pass code: 3350 428#. From 23 August 2010 a replay will be available
on the Topotarget homepage www.topotarget.com. 


Topotarget A/S

For further information, please contact:

Francois Martelet, CEO: Direct: +45 39 17 83 43; Mobile: +45 51 32 83 41
Anders Vadsholt, CFO: Direct: +45 39 17 83 45; Mobile: +45 28 98 90 55


Background information

About Topotarget
Topotarget (NASDAQ OMX: TOPO) is a Scandinavian based international biotech
company headquartered in Denmark, dedicated to improve cancer therapies. In
collaboration with Spectrum Pharmaceuticals, Inc. Topotarget currently focuses
on the development in pivotal studies of its lead drug candidate, belinostat,
which has demonstrated a clear anti neoplastic effect in both hematological
malignancies and solid tumors. Belinostat can be used in combination with full
doses of chemotherapy, and is currently in a pivotal trial within PTCL
(peripheral T-cell lymphoma) and phase II in cancer of unknown primary (CUP).
Topotarget's key cancer drugs target HDAC, NAD+, mTOR, Fas ligand and
topoisomerase II. Savene®/Totect® is the first product on the market from
Topotarget's drug discovery technology. Totect® is marketed by the company's
own sales specialists in the US. The European rights to, Savene®, were divested
in March 2010 as a consequence of the focus to develop and commercialise
belinostat. For more information, please refer to www.topotarget.com. 

Topotarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. Topotarget cautions investors that
there can be no assurance that actual results or business conditions will not
differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
Topotarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks;  uncertainty of additional funding; Topotarget's history of
incurring losses and the uncertainty of achieving profitability; Topotarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against Topotarget's products, processes and
technologies; the ability to protect Topotarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability exposure; We disclaim any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events, or otherwise, unless required by law.